Current Report Filing (8-k)
September 02 2016 - 10:52AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 1, 2016
MEI Pharma, Inc.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-50484
|
|
51-0407811
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
11975 El Camino Real, Suite 101, San Diego, California 92130
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code: (858) 792-6300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any
of the following provisions (
see
General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
(b) On September 1, 2016, Leah Rush Cann, a member of the Board of
Directors (the Board) of MEI Pharma, Inc. (the Company) resigned from the Board, effective immediately. The resignation follows her appointment as Managing Director and Senior Biotechnology Analyst at Oppenheimer & Co.
Inc., a registered broker-dealer and investment advisory firm.
The decision of Ms. Cann to resign is not the result of any
disagreement with the Company on any matter relating to its operations, policies or practices. Following such resignation, the Board has decided to reduce its size to seven directors.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
MEI PHARMA, INC.
|
|
|
By:
|
|
/s/ Daniel P. Gold
|
|
|
Daniel P. Gold
|
|
|
Chief Executive Officer
|
Dated: September 2, 2016
MEI Pharma (NASDAQ:MEIP)
Historical Stock Chart
From Mar 2024 to Apr 2024
MEI Pharma (NASDAQ:MEIP)
Historical Stock Chart
From Apr 2023 to Apr 2024